NCT02553187Unknown4 期
A Prospective, Randomized, Controlled, Multicenter Study of Kanglaite Injection for the Treatment of Cancer Cachexia
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 入组人数
- 160
- 试验地点
- 1
- 主要终点
- Lean body mass
研究概览
简要总结
The purpose of the study is to explore the efficacy and safety of Kanglaite Injection in the treatment of patients with late-stage cancer cachexia.
详细描述
The study is a multicenter, prospective, randomized controlled study. The planned sample size is 160 subjects. These subjects will be randomized (1:1) to treatment group (i.e., standard therapy plus Kanglaite Injection) or control group (i.e., standard therapy plus blank control). The study population includes the patients with non small cell lung cancer (adenocarcinoma), colorectal carcinoma and pancreatic carcinoma, who are complicated with cachexia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed patients with stage III-IV non-small cell lung cancer (adenocarcinoma), colorectal carcinoma or pancreatic carcinoma, who are not eligible for surgery, interventional treatment and radiation therapy;
- •Confirmed patients with cachexia: weight loss greater than 5% in last six months, or BMI<20kg/m2 and weight loss greater than 2%, or in accordance with the diagnosis of sarcopenia and weight loss greater than 2%;
- •Patients who are not being treated with chemotherapy should have completed chemotherapy 14 days before randomization of this study;
- •For patients who are being treated with chemotherapy, the chemotherapy regimen should be confined to the regimens specified in the protocol; and the chemotherapy regimen, in general, are not allowed to be changed during the study period;
- •Patients are conscious and able to cooperate with the doctor to complete the disease-related examinations and evaluations;
- •ECOG performance status (PS) 0-3 for those who are not treated with chemotherapy; and ECOG PS 0-2 for those who are being treated with chemotherapy;
- •Expected survival period is more than 4 months;
- •Male or female aged 18 - 75 years;
- •Patients who are willing to participate in the study and sign the informed consent form.
排除标准
- •Any pathological type of non-small cell lung cancer (NSCLC) except adenocarcinoma;
- •Patients who are being treated with chemotherapy, the chemotherapy regimen is not among the regimens specified in the protocol;
- •Patients with cachexia caused by other reasons, e.g. severe hepatic dysfunction [Aspartate transaminase(AST)/Cerealthirdtransaminase(ALT) >5 times the ULN], severe renal dysfunction (Cr >1.5 times the ULN), uncontrolled thyroid disease, New York Heart Association (NYHA) class III-IV heart failure, AIDS etc.;
- •Any condition that may hinder the subject's completion of the study, including but not limited to severe uncontrollable organic diseases or infection, unstable angina pectoris, congestive heart failure, etc.;
- •Patients who are being treated with other anticancer traditional Chinese medicine (TCM), or those who may be treated with TCM after enrollment;
- •Patients with severe hepatic dysfunction: Scr >=1.5 times the ULN, ALT/AST/alkaline phosphatase (ALP) >=5 times the ULN, total bilirubin (TBIL) >=1.5 times the ULN;
- •Patients with severe abnormal lipid metabolism [TC>300mg/dl or Triglyceride(TG) >2.5 times the ULN], or those who are in lipid-lowering therapy;
- •Known or suspected diagnosis of metastatic encephaloma;
- •In treatment of or plan to receive treatment of molecular targeted drugs, eg,epidermal growth factor receptor
- •tyrosine kinase inhibitor (EGFR-TKI), anaplastic lymphoma kinase (ALK) inhibitor, anti-angiogenic agents (including monoclonal antibodies and endostatin), and cetuximab;
- •Patients present with an ECOG score>2 and require treatment of chemotherapy;
- •Patients with allergies or intolerability to the investigational product or its excipients;
- •Patients who are currently included in other clinical trials on antineoplastic drugs;
- •Patients who are not able to provide the Informed Consent Form (ICF);
- •Expected survival period is less than 4 months;
- •Female patient is pregnant or breast-feeding, and those patients at childbearing age who are not willing to use methods of contraception (including males);
- •Patients with symptomatic, uncontrolled nervous disorders, mental illness or psychiatric disorder;
- •Any condition, in the investigator's opinion, is not in the best interest of the subject (e.g., harming the subject's health) or potentially interferes with the evaluation of treatment according to this protocol.
研究组 & 干预措施
Treatment group
Experimental
Kanglaite Injection plus standard therapy.
干预措施: Kanglaite Injection (Drug)
结局指标
主要结局
Lean body mass
时间窗: 77days
Body weight
时间窗: 77days
次要结局
- Progression-free survival rate (PFS)(77days)
- Survival curve(77days)
- Eastern Cooperative Oncology Group score (ECOG)(77days)
- Quality of life score (QOL)(77days)
- Overall Survival (OS)(77days)
- Serum albumin(77days)
- Serum Lactic Acid(77days)
- Incidence of myelosuppression (%)(77days)
- Body Mass Index (BMI)(77days)
- Serum Prealbumin(77days)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
4 期
Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC)NSCLCNCT03986528Jie Li334
Unknown
不适用
A Multicenter Real World Study of Kanglaite for Cancer CachexiaCancer CachexiaNCT03631459Zhejiang Kanglaite Pharmaceutical Co.Ltd100,000
已完成
3 期
A Local Clinical Study for the Comparative Evaluation of Efficacy and Safety of Angal, Lozenges [Menthol] and ANTI-ANGIN® FORMULA, Lozenges, in Treatment of Patients With a Sore ThroatSore ThroatNCT03095521Sandoz228
已完成
4 期
Danhong Injection in the Treatment of Unstable Angina PectorisUnstable Angina PectorisNCT02007187China Academy of Chinese Medical Sciences160
已完成
3 期
A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a SulphonylureaDiabetes Mellitus, Type 2NCT01381900Janssen Research & Development, LLC678